|MDACC Study No:||2012-1159 (clinicaltrials.gov NCT No: NCT01711528)|
|Title:||Phase 1 Clinical Trial of A Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma|
|Principal Investigator:||Sheeba K. Thomas|
|Treatment Agent:||Bortezomib; Dexamethasone; Dinaciclib|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of dinaciclib that can be given in combination with bortezomib and
Dinaciclib is designed to stop cancer cells from dividing into new cancer
cells. It may also make cancer cells more sensitive to chemotherapy drugs.
Bortezomib is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.